Avery Heather LaChance, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dermatology | 12 | 2023 | 872 | 3.630 |
Why?
|
Scleroderma, Systemic | 6 | 2023 | 323 | 2.270 |
Why?
|
Dermatomyositis | 7 | 2023 | 224 | 2.060 |
Why?
|
Lupus Erythematosus, Discoid | 4 | 2023 | 49 | 1.270 |
Why?
|
Telemedicine | 5 | 2023 | 2872 | 1.160 |
Why?
|
Skin Diseases | 5 | 2022 | 1065 | 1.150 |
Why?
|
Scleroderma, Localized | 2 | 2022 | 79 | 1.000 |
Why?
|
Microstomia | 1 | 2023 | 11 | 0.970 |
Why?
|
Mixed Connective Tissue Disease | 1 | 2023 | 26 | 0.950 |
Why?
|
Keloid | 1 | 2023 | 50 | 0.920 |
Why?
|
Lichen Sclerosus et Atrophicus | 1 | 2023 | 28 | 0.890 |
Why?
|
Cicatrix, Hypertrophic | 1 | 2023 | 79 | 0.870 |
Why?
|
Silicone Gels | 1 | 2021 | 39 | 0.800 |
Why?
|
Connective Tissue Diseases | 2 | 2021 | 264 | 0.790 |
Why?
|
Skin Abnormalities | 1 | 2021 | 60 | 0.780 |
Why?
|
Granuloma, Foreign-Body | 1 | 2021 | 45 | 0.780 |
Why?
|
Buttocks | 1 | 2021 | 110 | 0.770 |
Why?
|
Decontamination | 1 | 2021 | 69 | 0.750 |
Why?
|
Medical Tourism | 1 | 2021 | 57 | 0.750 |
Why?
|
Competency-Based Education | 1 | 2020 | 211 | 0.670 |
Why?
|
Consumer Health Information | 1 | 2020 | 211 | 0.630 |
Why?
|
Fasciitis | 3 | 2023 | 65 | 0.590 |
Why?
|
Eosinophilia | 4 | 2023 | 541 | 0.590 |
Why?
|
Internship and Residency | 4 | 2022 | 5788 | 0.560 |
Why?
|
Leg | 1 | 2021 | 1116 | 0.550 |
Why?
|
Health Policy | 4 | 2021 | 2661 | 0.550 |
Why?
|
Social Justice | 1 | 2020 | 456 | 0.550 |
Why?
|
Drug Costs | 3 | 2022 | 1105 | 0.530 |
Why?
|
Piperidines | 3 | 2021 | 1602 | 0.490 |
Why?
|
Drug Approval | 1 | 2021 | 742 | 0.490 |
Why?
|
Foot Dermatoses | 1 | 2014 | 44 | 0.480 |
Why?
|
Health Education | 1 | 2020 | 1056 | 0.470 |
Why?
|
Health Services Accessibility | 3 | 2023 | 5137 | 0.470 |
Why?
|
Physicians | 2 | 2022 | 4567 | 0.460 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2014 | 85 | 0.450 |
Why?
|
Autoimmune Diseases | 2 | 2022 | 2133 | 0.450 |
Why?
|
Adrenal Cortex Hormones | 1 | 2021 | 1855 | 0.410 |
Why?
|
Education, Medical, Undergraduate | 1 | 2020 | 1008 | 0.400 |
Why?
|
Academic Medical Centers | 2 | 2021 | 2759 | 0.390 |
Why?
|
Vulnerable Populations | 3 | 2021 | 687 | 0.390 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2014 | 602 | 0.350 |
Why?
|
Graft vs Host Disease | 1 | 2022 | 2957 | 0.350 |
Why?
|
Mycophenolic Acid | 2 | 2022 | 343 | 0.330 |
Why?
|
Lupus Erythematosus, Systemic | 5 | 2023 | 2104 | 0.330 |
Why?
|
Insurance Coverage | 1 | 2020 | 1901 | 0.330 |
Why?
|
Humans | 62 | 2024 | 744343 | 0.330 |
Why?
|
Skin Neoplasms | 5 | 2022 | 5686 | 0.330 |
Why?
|
Remote Consultation | 2 | 2021 | 238 | 0.320 |
Why?
|
Referral and Consultation | 1 | 2020 | 3528 | 0.300 |
Why?
|
Amyloidosis | 1 | 2014 | 795 | 0.300 |
Why?
|
Healthcare Disparities | 1 | 2020 | 3158 | 0.250 |
Why?
|
Skin | 4 | 2022 | 4364 | 0.250 |
Why?
|
Health Expenditures | 3 | 2022 | 2348 | 0.240 |
Why?
|
United States | 12 | 2023 | 69872 | 0.240 |
Why?
|
Hyaluronoglucosaminidase | 1 | 2023 | 133 | 0.230 |
Why?
|
Cutis Laxa | 1 | 2023 | 29 | 0.220 |
Why?
|
Injections, Intralesional | 1 | 2023 | 276 | 0.220 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2024 | 215 | 0.210 |
Why?
|
Cosmetics | 1 | 2023 | 97 | 0.200 |
Why?
|
Ointments | 1 | 2021 | 59 | 0.200 |
Why?
|
Leadership | 2 | 2021 | 1357 | 0.200 |
Why?
|
Dominican Republic | 1 | 2021 | 76 | 0.200 |
Why?
|
Pityriasis Rubra Pilaris | 1 | 2021 | 12 | 0.200 |
Why?
|
Betamethasone | 1 | 2021 | 45 | 0.200 |
Why?
|
Gift Giving | 1 | 2022 | 80 | 0.200 |
Why?
|
Raynaud Disease | 1 | 2021 | 74 | 0.200 |
Why?
|
Melanoma | 2 | 2016 | 5510 | 0.190 |
Why?
|
Arthritis, Psoriatic | 1 | 2024 | 215 | 0.190 |
Why?
|
Hidradenitis Suppurativa | 1 | 2023 | 153 | 0.190 |
Why?
|
Erythema | 1 | 2021 | 257 | 0.180 |
Why?
|
Steroids | 2 | 2022 | 930 | 0.170 |
Why?
|
Insurance | 1 | 2021 | 111 | 0.170 |
Why?
|
Education, Medical, Graduate | 2 | 2022 | 2291 | 0.170 |
Why?
|
Retrospective Studies | 12 | 2023 | 77449 | 0.170 |
Why?
|
Paraproteinemias | 1 | 2021 | 246 | 0.170 |
Why?
|
Masks | 1 | 2021 | 197 | 0.170 |
Why?
|
Disinfection | 1 | 2021 | 191 | 0.170 |
Why?
|
Alopecia Areata | 1 | 2021 | 107 | 0.160 |
Why?
|
Indians, North American | 1 | 2022 | 355 | 0.160 |
Why?
|
Myotonic Dystrophy | 1 | 2019 | 78 | 0.160 |
Why?
|
Botulinum Toxins, Type A | 1 | 2021 | 213 | 0.160 |
Why?
|
Drug Therapy | 1 | 2021 | 497 | 0.160 |
Why?
|
Medicare Part D | 1 | 2022 | 328 | 0.160 |
Why?
|
Phototherapy | 1 | 2021 | 377 | 0.150 |
Why?
|
Hydroxychloroquine | 1 | 2021 | 412 | 0.150 |
Why?
|
Acne Vulgaris | 1 | 2021 | 302 | 0.140 |
Why?
|
Exanthema | 1 | 2021 | 501 | 0.140 |
Why?
|
Pandemics | 3 | 2021 | 8388 | 0.140 |
Why?
|
Patients | 1 | 2023 | 900 | 0.140 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2020 | 640 | 0.140 |
Why?
|
Psoriasis | 1 | 2024 | 898 | 0.130 |
Why?
|
Video Recording | 1 | 2020 | 949 | 0.130 |
Why?
|
Sarcoidosis | 1 | 2021 | 506 | 0.130 |
Why?
|
Th17 Cells | 1 | 2022 | 766 | 0.130 |
Why?
|
Medicare | 3 | 2023 | 6566 | 0.130 |
Why?
|
Pyrimidines | 3 | 2021 | 2942 | 0.130 |
Why?
|
Curriculum | 2 | 2020 | 3605 | 0.120 |
Why?
|
Cross-Sectional Studies | 5 | 2023 | 25043 | 0.120 |
Why?
|
Communicable Disease Control | 1 | 2020 | 857 | 0.120 |
Why?
|
Lower Extremity | 1 | 2021 | 1158 | 0.110 |
Why?
|
Carcinoma, Basal Cell | 1 | 2019 | 545 | 0.110 |
Why?
|
Administration, Oral | 1 | 2021 | 3913 | 0.110 |
Why?
|
Toes | 1 | 2014 | 206 | 0.110 |
Why?
|
Reproducibility of Results | 2 | 2022 | 19905 | 0.110 |
Why?
|
Income | 1 | 2022 | 1913 | 0.110 |
Why?
|
Female | 14 | 2023 | 380194 | 0.110 |
Why?
|
Aged | 8 | 2023 | 163280 | 0.100 |
Why?
|
Macrophage Migration-Inhibitory Factors | 1 | 2011 | 108 | 0.100 |
Why?
|
Rural Population | 1 | 2022 | 2210 | 0.100 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2016 | 709 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2021 | 4420 | 0.100 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6489 | 0.100 |
Why?
|
Adult | 10 | 2023 | 214055 | 0.090 |
Why?
|
Immunosuppressive Agents | 2 | 2022 | 4149 | 0.090 |
Why?
|
Venous Thromboembolism | 1 | 2023 | 1671 | 0.090 |
Why?
|
Insurance, Health | 1 | 2022 | 2494 | 0.090 |
Why?
|
Biopsy | 1 | 2021 | 6756 | 0.080 |
Why?
|
Massachusetts | 1 | 2021 | 8663 | 0.080 |
Why?
|
Public Health | 1 | 2021 | 2603 | 0.080 |
Why?
|
Sex Factors | 1 | 2021 | 10397 | 0.080 |
Why?
|
Treatment Outcome | 3 | 2023 | 63114 | 0.070 |
Why?
|
Male | 11 | 2022 | 350118 | 0.070 |
Why?
|
Communication | 1 | 2020 | 3749 | 0.070 |
Why?
|
Socioeconomic Factors | 1 | 2020 | 7785 | 0.070 |
Why?
|
Middle Aged | 8 | 2021 | 213383 | 0.060 |
Why?
|
Quality of Life | 2 | 2023 | 12804 | 0.060 |
Why?
|
Combined Modality Therapy | 1 | 2016 | 8642 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7181 | 0.050 |
Why?
|
Cohort Studies | 2 | 2021 | 40561 | 0.050 |
Why?
|
Genetic Testing | 1 | 2014 | 3444 | 0.050 |
Why?
|
Isotretinoin | 1 | 2022 | 114 | 0.050 |
Why?
|
Diagnosis, Differential | 3 | 2021 | 12959 | 0.050 |
Why?
|
Lupus Erythematosus, Cutaneous | 1 | 2021 | 58 | 0.050 |
Why?
|
Prescriptions | 1 | 2022 | 387 | 0.040 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2023 | 652 | 0.040 |
Why?
|
Genomics | 1 | 2014 | 5720 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 1 | 2021 | 20129 | 0.040 |
Why?
|
Patient Care Management | 1 | 2021 | 306 | 0.040 |
Why?
|
Personal Satisfaction | 1 | 2022 | 643 | 0.040 |
Why?
|
Nose | 1 | 2021 | 509 | 0.040 |
Why?
|
Temperature | 1 | 2023 | 2206 | 0.040 |
Why?
|
Vasculitis | 1 | 2021 | 519 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2022 | 1681 | 0.040 |
Why?
|
Canada | 1 | 2022 | 2065 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2021 | 1184 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2016 | 25625 | 0.030 |
Why?
|
Prognosis | 1 | 2016 | 29063 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2016 | 588 | 0.030 |
Why?
|
Interdisciplinary Communication | 1 | 2021 | 950 | 0.030 |
Why?
|
Goals | 1 | 2020 | 706 | 0.030 |
Why?
|
Infant | 1 | 2016 | 35136 | 0.030 |
Why?
|
Career Choice | 1 | 2020 | 744 | 0.030 |
Why?
|
Pyrroles | 1 | 2021 | 1146 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2016 | 981 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2011 | 15540 | 0.030 |
Why?
|
Child, Preschool | 1 | 2016 | 41006 | 0.030 |
Why?
|
Extremities | 1 | 2019 | 865 | 0.030 |
Why?
|
Head | 1 | 2019 | 880 | 0.030 |
Why?
|
Qualitative Research | 1 | 2022 | 2682 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 21683 | 0.030 |
Why?
|
Young Adult | 2 | 2016 | 56430 | 0.030 |
Why?
|
Face | 1 | 2019 | 994 | 0.030 |
Why?
|
Teaching | 1 | 2020 | 1174 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2020 | 20822 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 15519 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1580 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2016 | 1970 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2021 | 4328 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3278 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2011 | 17446 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2022 | 3396 | 0.020 |
Why?
|
Child | 1 | 2016 | 77709 | 0.020 |
Why?
|
Adolescent | 1 | 2016 | 85781 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10388 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2024 | 9274 | 0.020 |
Why?
|
Pain | 1 | 2021 | 4986 | 0.020 |
Why?
|
Risk Factors | 2 | 2023 | 72290 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4445 | 0.020 |
Why?
|
Age Factors | 1 | 2021 | 18370 | 0.020 |
Why?
|
Emergency Service, Hospital | 1 | 2023 | 7659 | 0.020 |
Why?
|
Risk Assessment | 1 | 2023 | 23338 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14722 | 0.010 |
Why?
|
Genotype | 1 | 2011 | 12951 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2023 | 35421 | 0.010 |
Why?
|
Phenotype | 1 | 2011 | 16365 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2011 | 21746 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2016 | 57776 | 0.010 |
Why?
|